Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
Authors
Keywords
-
Journal
mAbs
Volume 8, Issue 3, Pages 593-603
Publisher
Informa UK Limited
Online
2016-02-27
DOI
10.1080/19420862.2015.1136043
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population
- (2015) Honglin Song et al. JOURNAL OF CLINICAL ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations
- (2012) C. Andrew Boswell et al. AAPS Journal
- Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
- (2012) Narendra Chirmule et al. AAPS Journal
- Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response
- (2012) H. Wong et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- A strategy for risk mitigation of antibodies with fast clearance
- (2012) Isidro Hötzel et al. mAbs
- Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
- (2012) C. V. Pastuskovas et al. MOLECULAR CANCER THERAPEUTICS
- Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice
- (2011) Daniela Bumbaca et al. BRITISH JOURNAL OF PHARMACOLOGY
- Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets
- (2011) Pauline L Martin et al. BRITISH JOURNAL OF PHARMACOLOGY
- Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets
- (2011) Peter J Bugelski et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood Flow
- (2011) C. Andrew Boswell et al. PLoS One
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Effect of Immune Complex Formation on the Distribution of a Novel Antibody to the Ovarian Tumor Antigen CA125
- (2010) C. V. Pastuskovas et al. DRUG METABOLISM AND DISPOSITION
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and Evaluation of a Novel Method for Preclinical Measurement of Tissue Vascular Volume
- (2010) C. Andrew Boswell et al. MOLECULAR PHARMACEUTICS
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody
- (2008) Wim K. Bleeker et al. BRITISH JOURNAL OF HAEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started